Results of the international MRC UKALLXII/ECOG E2993 trial. Out of the  1 752 patients who achieved CR, 11·7% underwent autologous and 40·6%  allogeneic transplant, while in CR1. Of the autologous patients, 43·2%  relapsed early and 3·4% relapsed late. However, among the allogeneic  patients, 13·2% relapsed early and only 1·3%...

Excellent review. The most of the newly approved drugs are for pts >75  years. The "problems"  of the approval trials are discussed. AS the  authro points: Don’t trust the horse, Trojans. Whatever it is, I fearthe Greeks even  bearing gifts.)—Virgi Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou,...

A combination of phenotypic and functional immune assays enables risk-stratification of patients with viral infections after transplantFunctional immune monitoring can help identify patients in need of additional antiviral intervention Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

A retrospective study, The combination of thiotepa, busulfan fludarabine (TBF) reduces the risk of relapse in patients with remission AML, as compared to myeloablative busulfan fludarabine (BUFLU)The effect is independt of donor type and GvHD prophylaxis. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

A quiz presentation with real examples. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas